Shape-shifting and tumor suppression by PLZF

Oncotarget

Volumn 1, Issue 1, 2010, Pages 3-5

  Hobbs, Robin M ^a   Pandolfi, Pier Paolo ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MYC PROTEIN; PROMYELOCYTIC LEUKEMIA ZINC FINGER PROTEIN; RAC PROTEIN; RAS PROTEIN; RETINOIC ACID RECEPTOR ALPHA; RHO KINASE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; ACTA2 PROTEIN, HUMAN; ACTIN; KRUPPEL LIKE FACTOR; ZBTB16 PROTEIN, HUMAN; ZINC FINGER PROTEIN;

ARTICLE; CANCER INHIBITION; CANCER STEM CELL; CELL CYCLE ARREST; CELL SHAPE; CELL STRUCTURE; CELL TRANSFORMATION; CHICKEN; CHROMOSOME TRANSLOCATION 11; CHROMOSOME TRANSLOCATION 17; CYTOSKELETON; EPITHELIAL MESENCHYMAL TRANSITION; FIBROBLAST; HUMAN; LEUKEMOGENESIS; NONHUMAN; ONCOGENE C MYC; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; PROTEIN TARGETING; TUMOR INVASION; GENETICS; METABOLISM; NEOPLASM; PATHOLOGY; PHYSIOLOGY; TUMOR SUPPRESSOR GENE;

ACTINS; CELL SHAPE; CYTOSKELETON; GENES, TUMOR SUPPRESSOR; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; NEOPLASMS; ZINC FINGERS;

EID: 79952338410     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.102     Document Type: Article

References (22)

1. Barna M, Hawe N, Niswander L, Pandolfi PP. Plzf regulates limb and axial skeletal patterning. Nat Genet 2000; 25:166- 172.
2. Buaas FW, Kirsh AL, Sharma M, McLean DJ, Morris JL, Griswold MD, de Rooij DG, Braun RE. Plzf is required in adult male germ cells for stem cell self-renewal. Nat Genet 2004; 36:647-652.
3. Costoya JA, Hobbs RM, Barna M, Cattoretti G, Manova K, Sukhwani M, Orwig KE, Wolgemuth DJ, Pandolfi PP. Essential role of Plzf in maintenance of spermatogonial stem cells. Nat Genet 2004; 36:653-659.
4. Doulatov S, Notta F, Rice KL, Howell L, Zelent A, Licht JD, Dick JE. PLZF is a regulator of homeostatic and cytokineinduced myeloid development. Genes Dev 2009; 23:2076- 2087.
5. He LZ, Bhaumik M, Tribioli C, Rego EM, Ivins S, Zelent A, Pandolfi PP. Two critical hits for promyelocytic leukemia. Mol Cell 2000; 6:1131-1141.
6. Kelly KF, Daniel JM. POZ for effect--POZ-ZF transcription factors in cancer and development. Trends Cell Biol 2006; 16:578-587.
7. Piazza F, Costoya JA, Merghoub T, Hobbs RM, Pandolfi PP. Disruption of PLZP in mice leads to increased T-lymphocyte proliferation, cytokine production, and altered hematopoietic stem cell homeostasis. Mol Cell Biol 2004; 24:10456-10469.
8. Melnick A, Carlile G, Ahmad KF, Kiang CL, Corcoran C, Bardwell V, Prive GG, Licht JD. Critical residues within the BTB domain of PLZF and Bcl-6 modulate interaction with corepressors. Mol Cell Biol 2002; 22:1804-1818.
9. David G, Alland L, Hong SH, Wong CW, DePinho RA, Dejean A. Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemiaassociated PLZF protein. Oncogene 1998; 16:2549-2556.
10. Chen Z, Brand NJ, Chen A, Chen SJ, Tong JH, Wang ZY, Waxman S, Zelent A. Fusion between a novel Kruppel-like zinc finger gene and the retinoic acid receptor-alpha locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia. EMBO J 1993; 12:1161-1167.
11. Chen Z, Guidez F, Rousselot P, Agadir A, Chen SJ, Wang ZY, Degos L, Zelent A, Waxman S, Chomienne C. PLZF-RAR alpha fusion proteins generated from the variant t(11;17) (q23;q21) translocation in acute promyelocytic leukemia inhibit ligand-dependent transactivation of wild-type retinoic acid receptors. Proc Natl Acad Sci U S A 1994; 91:1178- 1182.
12. Guidez F, Parks S, Wong H, Jovanovic JV, Mays A, Gilkes AF, Mills KI, Guillemin MC, Hobbs RM, Pandolfi PP, de The H, Solomon E, Grimwade D. RARalpha-PLZF overcomes PLZF-mediated repression of CRABPI, contributing to retinoid resistance in t(11;17) acute promyelocytic leukemia. Proc Natl Acad Sci U S A 2007; 104:18694-18699.
13. Dong S, Zhu J, Reid A, Strutt P, Guidez F, Zhong HJ, Wang ZY, Licht J, Waxman S, Chomienne C, Chen Z, Zelent A, Chen SJ. Amino-terminal protein-protein interaction motif (POZ-domain) is responsible for activities of the promyelocytic leukemia zinc finger-retinoic acid receptor-alpha fusion protein. Proc Natl Acad Sci U S A 1996; 93:3624-3629.
14. Shaknovich R, Yeyati PL, Ivins S, Melnick A, Lempert C, Waxman S, Zelent A, Licht JD. The promyelocytic leukemia zinc finger protein affects myeloid cell growth, differentiation, and apoptosis. Mol Cell Biol 1998; 18:5533-5545.
15. Yeyati PL, Shaknovich R, Boterashvili S, Li J, Ball HJ, Waxman S, Nason-Burchenal K, Dmitrovsky E, Zelent A, Licht JD. Leukemia translocation protein PLZF inhibits cell growth and expression of cyclin A. Oncogene 1999; 18:925- 934.
16. McConnell MJ, Chevallier N, Berkofsky-Fessler W, Giltnane JM, Malani RB, Staudt LM, Licht JD. Growth suppression by acute promyelocytic leukemia-associated protein PLZF is mediated by repression of c-myc expression. Mol Cell Biol 2003; 23:9375-9388.
17. Kikugawa T, Kinugasa Y, Shiraishi K, Nanba D, Nakashiro K, Tanji N, Yokoyama M, Higashiyama S. PLZF regulates Pbx1 transcription and Pbx1-HoxC8 complex leads to androgen- independent prostate cancer proliferation. Prostate 2006; 66:1092-1099.
18. Felicetti F, Errico MC, Bottero L, Segnalini P, Stoppacciaro A, Biffoni M, Felli N, Mattia G, Petrini M, Colombo MP, Peschle C, Care A. The promyelocytic leukemia zinc fingermicroRNA- 221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms. Cancer Res 2008; 68:2745-2754.
19. Shiraishi K, Yamasaki K, Nanba D, Inoue H, Hanakawa Y, Shirakata Y, Hashimoto K, Higashiyama S. Pre-B-cell leukemia transcription factor 1 is a major target of promyelocytic leukemia zinc-finger-mediated melanoma cell growth suppression. Oncogene 2007; 26:339-348.
20. Shi J, Vogt PK. Posttranslational regulation of Myc by promyelocytic leukemia zinc finger protein. Int J Cancer 2009; 125:1558-1565.
21. Frame MC, Brunton VG. Advances in Rho-dependent actin regulation and oncogenic transformation. Curr Opin Genet Dev 2002; 12:36-43.
22. Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev 2009; 28:15-33.